Signaling pathways
-
BA6949 VelagliflozinSummary: Velagliflozin is an orally available sodium-glucose cotransporter protein 2 inhibitor with antidiabetic activity. - BA6950 EnavogliflozinSummary: Enavogliflozin (DWP-16001) acts as an antidiabetic active molecule.
- BA6951 TianagliflozinSummary: Tianagliflozin is a sodium/glucose cotransporter protein 2 inhibitor.
- BA6952 RemogliflozinSummary: Remogliflozin is a potent and selective inhibitor of the human and rat sodium-glucose cotransporter 2.
- BA6953 T-1095Summary: T-1095 is a selective and orally active inhibitor of Na-glucose cotransporter proteins with 22.8 μM and 2.3 μM against human SGLT1 and SGLT2, respectively.
- BA6954 LuseogliflozinSummary: Luseogliflozin (TS071) is a potent, selective, and orally active inhibitor of sodium-glucose cotransporter protein 2.
- BA6955 HSK0935Summary: HSK0935 is a potent, highly selective, orally available inhibitor.
- BA6956 LTGO-33Summary: LTGO-33 is a potent and selective voltage-gated sodium channel inhibitor.
- BA6957 TPC2-A1-PSummary: TPC2-A1-P is a potent membrane-permeable two-pore channel 2 agonist (=10.5 μM) that acts by mimicking the physiological actions of PI(3,5)P2.
- BA6958 SuzetrigineSummary: Suzetrigine (VX-548) is an orally active and highly selective inhibitor with analgesic effects.